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BACKGROUND: Macrolide antibiotics such as erythro-
mycin and roxithromycin (RXM) have an anti-inflam-
matory effect that may account for their clinical
benefit in the treatment of chronic airway inflamma-
tory diseases. However, the precise mechanism of
this anti-inflammatory effect is not well understood.
Purpose: The influence of RXM on matrix metallo-
proteinase (MMP)-9 production from neutrophils in
response to lipopolysaccharide (LPS) stimulation was
examined in vitro.
Methods: Neutrophils prepared from normal human
peripheral blood (1 /10
5 cells/ml) were treated with
various concentrations of RXM for 1 h, and then
stimulated with 1.0 mg/ml of LPS in the presence of
the agent for 24 h. MMP-9 and tissue inhibitor of
metalloproteinase (TIMP)-1 levels in culture super-
natants were examined by enzyme-linked immuno-
sorbent assay.
Results: Addition of RXM at more than 5.0 mg/ml into
cell cultures caused significant suppression of MMP-9
production, which was increased by LPS stimulation.
However, the ability of cells to produce TIMP-1 was
not affected by RXM treatment, even when the cells
were cultured in the presence of agent at 10.0 mg/ml.
We then examined the influence of RXM on transcrip-
tional factor, nuclear factor-kB and activator protein
(AP)-1 activation by LPS stimulation. RXM exerted
suppressive action on NF-kB (P50 and P65) activation
when the cells were cultured for 4 h at more than
5.0 mg/ml of the agent. RXM at more than 2.5 mg/ml
also suppressed AP-1 (Fra 1 and Jun B) activation in
4-h cultured cells. We finally examined the influence
of RXM on MMP-9 mRNA expression in neutrophils.
Addition of RXM into cell cultures at more than
5.0 mg/ml caused significant inhibition of mRNA
expression, which was enhanced by LPS stimulation
for 12 h.
Conclusion: These results strongly suggest that RXM
inhibits neutrophil transmigration into inflamma-
tory sites and results in favorable modification of
the clinical status of inflammatory diseases.
Key words: Macrolide antibiotic, Roxithromycin, Neutro-
phil, Matrix metalloproteinase-9, Suppression
Mediators of Inflammation, 13(5/6), 313 /319 (October/November 2004)
Suppression of matrix
metalloproteinase-9 production
from neutrophils by a macrolide
antibiotic, roxithromycin, in vitro
Ken-Ichi Kanai
1, Kazuhito Asano
2,CA,
Tadashi Hisamitsu
2 and Harumi Suzaki
1
1Department of Otolaryngology and
2Department of
Physiology, School of Medicine, Showa University, 1-
5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
CACorresponding Author
Tel:   /81 3 3784 8110
Fax:   /81 3 3784 5368
E-mail: asanok@med.showa-u.ac.jp
Introduction
Low-dose and long-term use of 14-membered
macrolide antibiotics (e.g. erythromycin and trolean-
dromycin, etc.) is reported to be effective in the
treatment and the management of patients with
chronic airway inflammatory diseases such as diffuse
panbronchiolitis (DPB) and chronic rhinosinusitis
(CR).
1 3 Recently, azithromycin, a newly synthesized
16-membered macrolide antibiotic, is also reported to
be effective in the improvement of lung function in
cystic fibrosis (CF).
4,5 Although there is circumstantial
evidence that the therapeutic mode of the macrolides
on these inflammatory diseases may be due to their
anti-inflammatory action rather than anti-microbiolo-
gical effects,
3,6 the precise mechanisms of this
macrolide therapy are not well understood.
Accumulation of neutrophils around the small and
large airways is reported to be the characteristic
feature of DPB and CF.
3,7 Airway lavage fluids from
the patients with DPB and CF commonly contain
large number of inflammatory cells, especially neu-
trophils and high amounts of neutrophil-derived
chemical mediators as well as the neutrophil granule
enzyme myeloperoxidase and elastase.
3,7,8 Neutro-
phil numbers and neutropil-derived enzymatic activ-
ity were also significantly elevated in nasal secretions
from patients with CR compared with that from
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9 Successful macrolide treatment is
reported to cause normalization of these neutrophilic
inflammatory responses along with favorable mod-
ification of clinical status of the diseases,
2,3 suggesting
that neutrophils play essential roles in the develop-
ment of chronic airway inflammatory diseases as one
of the final effector cells.
Recruitment of circulating immune cells including
neutrophils into the inflammatory sites involves
traversing both the capillary walls and the intersti-
tium.
10,11 To traverse these barriers, inflammatory
cells adhere to endothelial cells and degrade extra-
cellular matrix (ECM) proteins.
10,11 The basement
membrane is well accepted to be a unique structure
composed of several types of molecules, including
type IV and type V collagens, laminin and fibronec-
tin.
11,12 The degradation of ECM proteins including
basement membrane proteins by monocytes/macro-
phages is accomplished, in part, by the secretion of
the matrix metalloproteinases (MMPs) such as MMP-2
and MMP-9, which are selectively degrade type IV
and type V collagens in their native forms.
12 Recent
reports showed that the inflammatory cells, such as
neutrophils and eosinophils,
13,14 as well as macro-
phages,
11 secrete MMPs, especially MMP-9, to migrate
through the basement membrane. In the present
study, therefore, we examined the influence of
macrolide antibiotics on MMP production through
the choice of roxithromycin (RXM) and human
peripheral blood neutrophils in vitro.
Materials and methods
Reagents
RXM was kindly donated by Aventis Pharmaceutical
Co. Ltd (Tokyo, Japan) as a preservative-free pure
powder. The agent was firstly dissolved in 100%
methyl alcohol at 20.0 mg/ml and then diluted with
antibiotic-free RPMI-1640 medium (Sigma Chemicals
Co. Ltd, St Louis, MO, USA) supplemented with 10%
heat-inactivated fetal calf serum (RPMI-FCS; Irvine
Scientific, Inc., Santa Ana, CA, USA) at appropriate
concentrations for experiments. Lipopolysaccharide
(LPS) extracted from Klebsiella pneumoniae was
purchased from Sigma Chemicals Co. Ltd and dis-
solved with RPMI-FCS. The basement membrane
matrix (Matrigel) was purchased from Becton Dick-
inson Labware (Bedford, MA, USA).
Preparation of neutrophils
Heparinized human venous blood was obtained from
five healthy volunteers (all male, aged 25 /50 years)
under written informed consent. The blood was
diluted twice with phosphate-buffered saline (PBS)
and overlayered onto the Mon-Poly Resolving Med-
ium (Flow Laboratories, Inc., MacLean, VA, USA).
After centrifugation at 1000  /g for 30 min at 258C,
peripheral blood leukocytes (PBL) were collected
from the plasma /medium interface and washed
three times with PBS. CD16
  cells, neutrophils,
were separated from PBL using a magnetic cell
separator (Milteny Biotec, Bergisch Gladbach, Ger-
many) as described previously.
15 In brief, PBL were
labeled with human CD16 monoclonal antibody-
coated magnetic beads (Milteny Biotec) and were
then applied to the column placed in the separator.
After removing unlabeled cells by washing with PBS,
the column was removed from the separator and
rinsed with PBS. The entire effluated cells were
washed twice with RPMI-FCS, resuspended at a
concentration of 1  /10
5 cells/ml and used as neu-
trophils. The purity of neutrophils was more than
97% as judged by Giemsa’s stein.
Cell culture
Neutrophils (1  /10
5 cells/ml) were introduced
into each well of 24-well plates that contained
1.0 mg/ml of LPS and various concentrations of RXM
in a final volume of 2.0 ml. The plates were then
maintained at 378C in a humidified atmosphere with
5% CO2. The supernatant was collected 24 h later and
stored at   /408C until assayed for the levels of both
MMP and tissue inhibitor of metalloproteinases
(TIMP). To prepare cells examining for transcrip-
tional factor activity and mRNA expression, neutro-
phils were cultured in a similar manner for 4 h and 12
h, respectively. In all experiments, RXM treatment
was started 1 h before LPS stimulation.
Transmigration assay
The migration activity of neutrophils was assessed by
a kind of Boyden-chamber assay as described
previously with some modifications.
11 Transwell
chambers fitted with polyvinylpyrolidine-free poly-
carbonate filters with 3.0 mm pore size were used
(Corning Coster Corp., Cambridge, MA, USA). Each
filter was coated with 50 ml of Matrigel (200 mg) in
RPMI-1640 medium without fetal calf serum and
incubated for 1 h at 378C to make a thin, continuous
barrier on the top of the filter. Neutrophils pretreated
with various concentrations of RXM for 1 h were
seeded onto the coated membrane of the upper
chamber of the Transwell at 1  /10
6 cells in 500 mlo f
RPMI-FCS, and stimulated with 1.0 mg/ml of LPS in
the presence of RXM. The lower chamber was filled
with 1.0 ml of RPMI-FCS that contained the same
concentration of both LPS and RXM as in the
corresponding culture wells (the upper chamber).
The cells were then cultured for 24 h, and the
medium was harvested from the lower chamber.
The number of cells in the medium was counted
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adhered to both the bottom of the lower chamber
and the lower surface of membrane was also
counted.
Assay for MMP-9 and TIMP-1
MMP-9 and TIMP-1 levels in culture supernatants
were examined in duplicate by commercially avail-
able MMP-9 and TIMP-1 enzyme-linked immunosor-
bent assay (ELISA) test kits (Amersham Biosciences
Corp., Piscataway, NJ, USA) according to the manu-
facturer’s recommendation. The sensitivity of each
ELISA kit for MMP-9 and TIMP-1 was 0.6 ng/ml and
3.0 ng/ml, respectively.
Assay for mRNA expression
mRNA expression was examined by means of reverse
transcriptase-polymerase chain reaction (RT-PCR).
Poly A
  mRNA was extracted from neutrophils with
mMACS mRNA isolation kits (Milteny Biotec) accord-
ing to the manufacturer’s instructions. The first-strand
cDNA synthesis from 1.0 mg of mRNA was performed
with a Superscript cDNA synthesis kit (Invitrogen
Corp, Carlsbad, CA, USA). Amplification of cDNA
(1.0 ml) was performed with a Takara PCR Amplifica-
tion kit (Takara Shuzo, Co., Ltd, Shizuoka, Japan)
using specific primers for MMP-9 and b-actin in a final
volume of 30 ml. The primers used for RT-PCR were
5?-CCCACATTTGACGTCCAGAGAAGAA-3? (sense)
and 5?-GTTTTTGATGCTATTGGCTGAGATCCA-3?
(anti-sense) for MMP-9, and 5?-CGGAACCGCT-
CATTGCC-3? and 5?-ACCCACACTGTGCCCATCTA-3?
for b-actin.
16 The PCR conditions were as follows:
4 min at 948C, followed by 30 cycles of 30 sec at 958C,
30 sec at 508C, and 30 sec at 708C. After cycling, there
was a DNA extension period of 2 min at 708C.
16 Each
PCR product (10 ml) was run on 3% agarose gels,
visualized by an ultraviolet illuminator after SYBR
Green (BioWhittaker Molecular Applications, Rock-
land, ME, USA) staining and photographed. The
intensity of mRNA levels was corrected by b-actin
transcripts calculated by a densitometer.
Assay for nuclear factor-kB and AP-1 activity
Nuclear factor (NF)-kB activity was analyzed by a
commercially available ELISA test kit (Active Motif,
Carlsbad, CA, USA) that contains sufficient reagents
and monoclonal antibodies against P50 and P65
according to the manufacturer’s recommended pro-
cedure. In brief, nuclear extract (5.0 mg protein) from
neutrophils was introduced into each well of 96-
well microtiter plates pre-coated with oligo-
nucleotide containing the NF-kB consensus site (5?-
GGGACTTTCC-3?) in a volume of 20.0 ml, and
incubated for 1 h at 258C. After washing three times,
100 ml of monoclonal antibody against P50 or P65
was added to the appropriate wells, and incubated
for a further 1 h at 258C. Anti-IgG horseradish
peroxidase conjugate in a volume of 100 ml was
then added and incubated for 1 h at 258C. Absor-
bance at 450 nm was measured after the addition of
tetramethylbenzine solution. AP-1 activity was also
examined by a commercially available ELISA test kit
(Active Motif) that contains sufficient reagents and
monoclonal antibodies to Fra 1 and Jun B in a similar
manner.
Statistical analysis
The statistical significance of the difference between
the control and experimental data was analyzed
using analysis of variance (ANOVA) followed by
Fisher’s PLSD test.
Results
Influence of RXM on neutrophil migration
The first experiments were undertaken to examine
whether neutrophils could degrade Matrigel, which is
a resembled basic membrane, and migrate through it
and whether RXM could inhibit neutrophil migration.
Although a Matrigel transwell filter could prevent
neutrophil migration (Fig. 1, Med. alone), stimulation
of neutrophils with LPS significantly enhanced the
ability of cells to migrate through Matrigel (Fig. 1, LPS
alone). This activity was significantly decreased by
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FIG. 1. Inﬂuence of RXM on neutrophil transmigration
assessed by transmigration assay. Neutrophils (1  /10
5
cells/500 ml) stimulated with 1.0 mg/ml of LPS in the presence
of various concentrations of RXM were added to the upper
chamber. A 1-ml sample of medium was added to the lower
chamber. After 24 h, the numbers of cells transmigrated
were counted. The data were expressed as mean percent
neutrophil migration9 /standard error (SE) of ﬁve different
subjects. *Signiﬁcant (pB /0.05) versus medium (Med.) alone,
**Signiﬁcant (pB /0.05) versus LPS alone.
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culture medium (Fig. 1).
Influence of RXM on MMP-9 and TIMP-1
production from neutrophils
The second set of experiments was designed to
examine the influence of RXM on MMP-9
and TIMP-1 production from neutrophils after LPS
stimulation. Neutrophils pretreated with various con-
centrations of RXM for 1 h were stimulated with
1.0 mg/ml of LPS in the presence of the agent for 24 h.
MMP-9 and TIMP-1 levels in culture supernatants
were examined by ELISA. As shown in Fig. 2, RXM
could suppress MMP-9 production from neutrophils,
which was increased by LPS stimulation. This sup-
pressive activity of RXM was first noted at 5.0 mg/ml.
On the other hand, RXM scarcely affected TIMP-1
production from neutrophils by LPS stimulation:
culture supernatants obtained from cells cultured
with 10.0 mg/ml RXM contained similar levels of
TIMP-1 (not significant) to that from cells cultured
without RXM (Fig. 3).
Influence of RXM on MMP-9 mRNA expression
in neutrophils
The third experiment was undertaken to examine
whether RXM could suppress MMP-9 mRNA expres-
sion and caused a decrease in MMP-9 levels in culture
supernatants. Neutrophils pretreated with various
concentrations of RXM for 1 h were stimulated with
1.0 mg/ml of LPS in the presence of the agent for 12 h,
and mRNA expression for MMP-9 was examined by
RT-PCR. The photographs in Fig. 4 clearly show that
addition of RXM at more than 5.0 mg/ml caused
inhibition of MMP-9 mRNA expression, which was
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FIG. 2. Inﬂuence of RXM on MMP-9 production from
neutrophils in response to LPS stimulation. Neutrophils
prepared from human peripheral blood (1  /10
5 cells/ml)
were stimulated with 1.0 mg/ml of LPS in the presence of
various concentrations of RXM for 24 h. MMP-9 levels in the
culture supernatants were assayed by ELISA. The data were
expressed as mean (ng/ml)9 /standard error (SE) of ﬁve
different subjects. *Signiﬁcant (pB /0.05) versus LPS alone.
Med., medium.
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FIG. 3. Inﬂuence of RXM on TIMP-1 production from
neutrophils in response to LPS stimulation. Neutrophils
prepared from human peripheral blood (1  /10
5 cells/ml)
were stimulated with 1.0 mg/ml of LPS in the presence of
various concentrations of RXM for 24 h. TIMP-1 levels in the
culture supernatants were assayed by ELISA. The data were
expressed as mean (ng/ml)9 /standard error (SE) of ﬁve
different subjects. *Not signiﬁcant (p  /0.05) versus LPS
alone. Med., medium.
FIG. 4. Inﬂuence of RXM on MMP-9 mRNA expression in
neutrophils stimulated with LPS. Neutrophils prepared from
human peripheral blood (1  /10
5 cells/ml) were stimulated
with 1.0 mg/ml of LPS in the presence of various concentra-
tions of RXM for 12 h. mRNA expression was assessed by
RT-PCR. Photographs are one typical result out of ﬁve
different subjects. Graphs show the ratio of MMP-9:b-actin
obtained from ﬁve different subjects. *Signiﬁcant (pB /0.05)
versus LPS alone.
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graphs showing the ratio of MMP-9/b-actin obtained
from five different subjects.
Suppression of transcriptional factor activation
by RXM in neutrophils
The final set of experiments was carried out to
examine the influence of RXM on transcriptional
factor activity induced by LPS stimulation. Neutro-
phils pretreated with various concentrations of RXM
for 1 h were stimulated with 1.0 mg/ml of LPS in the
presence of the agent for 4 h, and the activity of both
NF-kB and AP-1 in the nucleus was examined by
ELISA. Figure 5 shows that addition of RXM at more
than 5.0 mg/ml into cell cultures caused significant
suppression of NF-kB (P50 and P65) activity, which is
enhanced by LPS stimulation. It is also showed that
RXM exerts suppressive effect on AP-1 (Fra 2 and Jun
B) activation induced by LPS stimulation in neutro-
phils (Fig. 6).
Discussion
Various studies on the action of macrolide antibiotics,
especially 14-membered macrolide antibiotics, other
than their antibiotic actions have been reported,
1 6,11
drawing attention to the macrolides as immunomo-
dulators. Erythromycin, the most famous macrolide
antibiotic, has been reported to suppress the produc-
tion of interleukin-8
17 and Cl
  secretion
18 from
epithelial cells. It is also reported that erythromycin
and RXM exert anti-lymphocytic activity, including
inhibition of inflammatory cytokine production in
vitro and in vivo.
19 22 We therefore considered it of
great interest to examine whether macrolide anti-
biotics could suppress MMP gelatinolytic activity,
which is an essential inducible gelatinase for mono-
cyte/macrophage and polymorphonuclear leukocyte
migration.
The present results clearly show that RXM could
suppress MMP-9, but not TIMP-1, production from
neutrophils induced by LPS stimulation in vitro.I ti s
also shown that this inhibitory action of RXM may be
at the transcriptional level.
Histological observations of DPB, CR and CF
revealed the thickening of the basement membrane
with predominant infiltration of polymorphonuclear
leukocytes, especially neutrophils.
3,7,9 These inflam-
matory changes are accompanied by edema and
extend to the airway wall.
3,7,9 Morphometric studies
in the lungs of DPB and CF showed significant
dilation of the acini of tracheal submucosal glands.
3,7
It is also observed that the bronchial mucosa features
excessive goblet cells and, focally, a metaplastic
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FIG. 5. Inﬂuence of RXM on NF-kB activation in neutrophils by LPS stimulation. Neutrophils prepared from human peripheral
blood (1  /10
5 cells/ml) were stimulated with 1.0 mg/ml of LPS in the presence of various concentrations of RXM for 4 h. NF-kB
(P50 and P65) activity in the nucleus were assayed by ELISA. The data are expressed as the mean optical density (OD) at 450
nm9 /standard error (SE) of ﬁve different subjects. *Signiﬁcant (pB /0.05) versus LPS alone. Med., medium.
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3,7,23 In cases of CR, pathological
observation showed the loss of differentiated epithe-
lial cells ranging from denuted epithelium to basal
cell hyperplasia often associated with squamous
metaplasia.
24 Hyperplasia and hypertrophy of nasal
acinar cells in nasal mucosa were also observed.
25
These histological changes are now called airway
tissue remodeling, and involve extensive alterations
of the tissue ECM.
26
The ECM is involved in tissue homeostasis and in
pathologic conditions such as tumor invasion and
inflammation.
26 Two groups of proteins, MMPs and
their counter-regulatory inhibitors TIMPs, are ac-
cepted to be the important factors for maintenance
of the ECM homeostasis. The MMPs are a large family
of zinc-dependent and calcium-dependent endopep-
tidases with distinct substrate specificities that can
degrade most components of the ECM.
27 Of the MMP
family, MMP-9 (named gelatinase B) is the major
proteinase that induces airway remodeling.
26 In
addition, MMP-9 is produced by numerous cell types,
including neutrophils in response to inflammatory
stimulations, and is essential for the migration of
neutrophils across the basement membrane to pro-
pagate inflammation.
28,29 MMP-9 also appears to be
responsible for microvascular permeability leading to
edema and enhancement of cell transmigration.
28,29
From these reports, it is possible that the inhibitory
action of RXM on MMP-9 production from neutro-
phils may be one of therapeutic mechanisms of RXM
on chronic airway diseases. This suggestion may be
supported by the observation that erythromycin
could suppress the ability of U937, a human histio-
cytic lymphoma cell line, to produce MMP-9 in vitro
and also inhibited transmigration of U937 cells
through a 12 mm pore size filter coated with laminin
and type IV collagen.
11
Most MMPs are secreted from the cells as inactive
proenzymes and cleaved extracellularly to produce
the active forms.
30 The extracellular activity of MMPs
is regulated by TIMPs, which are secreted by the
same cell types that produce MMPs.
30 The present
results clearly showed that RXM scarcely affected the
ability of neutrophils to produce TIMP-1, suggesting
that MMP-9 secreted in small amounts during RXM
treatment is inactivated by TIMP-1, and results in the
inhibition of ECM remodeling and inflammatory
responses.
Previous studies clearly showed that the produc-
tion of several mediators (e.g. inflammatory cyto-
kines and chemokines) and various lytic enzymes by
neutrophils is typically preceded by an accumulation
of the corresponding mRNA transcripts,
31,32 which
largely depend on several types of transcriptional
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FIG. 6. Inﬂuence of RXM on AP-1 activation in neutrophils by LPS stimulation. Neutrophils prepared from human peripheral
blood (1  /10
5 cells/ml) were stimulated with 1.0 mg/ml of LPS in the presence of various concentrations of RXM for 4 h. AP-1
(Fra 1 and Jun B) activity in the nucleus was assayed by ELISA. The data are expressed as the mean optical density (OD) at 450
nm9 /standard error (SE) of ﬁve different subjects. *Signiﬁcant (pB /0.05) versus LPS alone. Med., medium.
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32 Among them, transcriptional fac-
tors, NF-kB and AP-1 are widely recognized as central
regulators in neutrophil activation induced by LPS
and tumor necrosis factor-alpha stimulation.
17,32 It is
also recognized that MMP production requires the
translocation of both NF-kB and AP-1 to the nucleus
and binding to promoter regions, which cause the
induction of MMP mRNA expression.
33,34 These
reports prompt us to examine the influence of RXM
on NF-kB and AP-1 activation, which may influence
the expression of MMP-9 mRNA by interacting
with the promoter region of the gene. The present
results clearly showed that RXM at a concentration of
5.0 mg/ml could suppress mRNA expression for MMP-
9 through the inhibition of transcriptional factor, NF-
kB and AP-1, activation induced by LPS stimulation.
Since the concentration of RXM (5.0 mg/ml)
showing the suppressive effect on MMP-9 produc-
tion in vitro is far below that in plasma levels
(7.5 /10.0 mg/ml) in the macrolide therapy,
21,22 the
efficacy of 14-membered macrolide antibiotics, espe-
cially RXM, in chronic airway inflammatory diseases
may be explained by these in vitro data suggesting
downregulating activity of the drugs on neutrophil
functions related to inflammation and tissue remo-
deling.
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